Amplia Therapeutics Ltd.ASX: ATX

Amplia Launches First Stage of Pivotal Narmafotinib Trial

· Issued by Amplia Therapeutics Ltd.

Filed with ASX · · 2 pages · English

Summary by 6ix AI

This study aims to explore a new daily dosing regimen of narmafotinib in combination with standard chemotherapy treatments. Patient enrollment is expected to begin in the fourth quarter of this year, with the study designed to assess safety, tolerability, and efficacy. The trial builds on previous positive data from earlier studies and is intended to support a future registrational submission to the FDA.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Amplia Therapeutics Ltd. on 6ix

Earlier from Amplia Therapeutics

Later from Amplia Therapeutics

All Amplia Therapeutics news releases